BMI, tobacco, and alcohol: Roles in glaucoma progression examined in study

News
Article

The primary findings were that a higher BMI was protective against glaucoma progression and use of tobacco and alcohol were not significantly associated with retinal nerve fiber layer change.

Man holding cigarette and whiskey glass at table Image credit: AdobeStock/Parkin

Image credit: AdobeStock/Parkin

A newly published study1 found that use of tobacco and alcohol did not significantly affect the rate of change of the retinal nerve fiber layer (RNFL), while a high body mass index (BMI) was associated with slower structural changes in the visual fields, according to Asmaa A. Youssif, MD, from the Duke Eye Center, Duke University, Durham, NC, and the Department of Ophthalmology, Assiut University Faculty of Medicine, Assiut, Egypt.

Youssif and colleagues explained that while studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

In light of that gap in the medical literature, the researchers set out to determine how the RNFL fared over time in patients with glaucoma in association with the BMI and tobacco and alcohol use.

A total of 2,839 eyes (1,584 patients) with glaucoma from the Duke Ophthalmic Registry were included. All patients had undergone at least 2 spectral-domain optical coherency tomography (SD-OCT) tests over a minimum 6-month follow-up.

Information about alcohol and tobacco use was obtained from electronic health records and the mean BMI was calculated.

The authors reported that the mean follow-up time was 4.7±2.1 years and each eye had undergone a mean of 5.1±2.2 SD-OCT tests. A history of tobacco or alcohol consumption was reported by 43% and 54% of patients, respectively, and 34% of patients were obese.

The primary findings were that a higher BMI was protective against glaucoma progression (0.014 µm/year slower per each 1 kg/m2 higher; p=0.011), and use of tobacco and alcohol were not significantly associated with RNFL change rates (p=0.473 and p=0.471, respectively). Patients who were had significantly faster rates of structural loss (−0.768 µm/year; p=0.002) compared with those who had a normal weight.

Reference:
  1. Youssif AA, Onyekaba N-A, Naithani R, et al. Social history and glaucoma progression: the effect of body mass index, tobacco and alcohol consumption on the rates of structural change in patients with glaucoma, Br J Ophthalmol. 2024;108:1694-1700.
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.